Author Information
Matthew Baggot

matt@baggot.net

Mr. Matthew Baggott has conducted psychopharmacology research for over a decade,
most recently at the University of California, San Francisco. He has  published on the pharmacology of entactogens, psychostimulants, and opiates.
 

Katherine Bonson, PhD

Team Pharmacologist, Controlled Substances Staff, Food and Drug Administration.
 
kbonson@codon.nih.gov

Dr. Katherine Bonson has studied the effects of drugs on serotonergic systems of the brain at the National Institute of Mental Health, the National Institute on Drug Abuse and Johns Hopkins University. She is particularly interested in hallucinogens and the ability of antidepressants to alter their effects in animals and humans. {Note that Dr. Bonson's statements are those of an individual pharmacologist, not an FDA representative, and that her chapter does not present official FDA positions.}
 

Gary Bravo M.D.,

3322 Chanate Road, Santa Rosa, CA 95404

glbravo@aol.com.

Dr. Gary Bravo is a staff psychiatrist for Sonoma County Mental Health in Santa Rosa, California.  While on the clinical faculty at the University of California -Irvine, he wrote about the effects of MDMA and worked with Dr. Charles Grob on the first federally-approved MDMA protocol.
He has also written articles on psychedelics and psychiatry, and transpersonal psychology.
 

Rick Doblin, PhD

rick@maps.org

2105 Robinson Avenue, Sarasota, Florida 34232

Dr. Rick Doblin is the president of MAPS, Multidisciplinary Association for Psychedelic Studies (www.maps.org) a group he founded in 1986 in order to develop MDMA into an FDA-approved  prescription medicine.  He received his Ph.D. in Public Policy from the Kennedy School of Government, Harvard University. His dissertation focused on the regulation of the medical uses of psychedelic drugs and marijuana.
 

Alex Gamma, PhD
Research Assistant, University Hospital of Psychiatry, Zurich, Switzerland

gamma@bli.unizh.ch

Dr. Alex Gamma is a biologist specializing in neuropsychopharmacology. For the past 5 years, he has been conducting basic experimental research into the acute effects of MDMA in healthy subjects, as well as clinical studies in long-term Ecstasy users.

 
George R. Greer M.D.
 
Medical Director, Heffter Research Institute
 
453 Cerrillos Road, Suite E, Santa Fe, NM  87501
 
george@newmexico.com

George Greer, M.D., and his wife, Requa Tolbert, M.S.N. a psychiatric nurse, administered MDMA over 100 times to 80 people as part of his clinical psychiatric practice from 1980 to 1985.  Their review of this work remains the largest published study of the therapeutic use of MDMA to date. In1985, Dr. Greer was involved in an extensive hearing process with the Drug
Enforcement Administration to keep MDMA available for medical research.  Dr. Greer is a Fellow of the American Psychiatric Association and Past President of the New Mexico District Branch.

 
Charles S. Grob, M.D.
 
Director of the Division of Child and Adolescent Psychiatry, Harbor-UCLA Medical Center
Professor of Psychiatry, UCLA School of Medicine

Box 498 Harbor-UCLA Medical Center,1000 W. Carson St., Torrance, CA 90509

Dr. Charles S. Grob conducted the first FDA approved research study examining the effects of MDMA on human volunteers, and is in the process of obtaining approval to investigate the effects of MDMA on end-stage cancer patients with severe psychological distress, existential anxiety and increasing isloation and alienation.  Dr. Grob has written extensively on the history of MDMA, the putative MDMA treatment paradigm and has provided a critical analysis of the neurotoxicity hypothesis.
 

Professor John A Henry, MBBS FRCP, FFAEM

Academic Department of Accident & Emergency Medicine, St Mary's Hospital, London W2 1NY

Professor Henry spent 15 years as a Consultant Physician at Guy's Hospital and the National Poisons Information Service, London, and took up his present post in 1997.  He highlighted and provided an explanation for the hyperthermic complications of MDMA.  He was the first to describe hepatotoxicity due to MDMA, and also described the first cases of hyponatraemia.  He has demonstrated, through clinical research, that vasopressin release is a pharmacological effect of MDMA.
 

Julie Holland, MD

Clinical Assistant Professor of Psychiatry, New York University School of Medicine

drholland.com

Bellevue Hospital Comprehensive Psychiatric Emergency Program
462 First Avenue, GN-7, New York, NY  10016

Dr. Holland is a physician in the psychiatric emergency room at Bellevue Hospital, with a private practice in New York City.  She has been researching, writing, and speaking about the therapeutic potential of MDMA since 1985. She received the 1994 National Institute of Mental Health Outstanding Resident Award for her clinical research on schizophrenia.
 

Karl Jansen, MD, PhD, MRCPsych

K@BTInternet.com

52 Fellows Rd, Belsize Park, London NW3 3LJ

Dr. Karl Jansen is a medical doctor and consultant psychiatrist who was engaged in full-time study of the human brain for 6 years. He also has a PhD in clinical pharmacology and is a member of the Royal College of Psychiatrists. He has made a special study of persons who use very large quantities of MDMA (20 pills per weekend) and ketamine, and often appears in Court as an expert witness.
 

Andrew M. Kleiman M.D.

Dept. of Psychiatry, Bellevue Hospital, 462 First Avenue, Room 20N11, NY, NY, 10016

Dr. Andrew Kleiman is a fourth year resident in Psychiatry at New York University Medical Center, Bellevue Hospital, in New York City. He is interested in clinical psychiatric research and is planning on establishing a private practice in psychiatry.
 

Mark Kleiman, PhD
 
Professor of Policy Studies, UCLA
Research Fellow, Program in Criminal Justice Policy and Management, Harvard
 
kleiman@ucla.edu

3250 Public Policy Building, UCLA, Los Angeles, CA 90095

Dr. Mark Kleiman is an internationally recognized expert on policy for substance abuse control.  He edits the Drug Policy Analysis Bulletin and chairs the Drug Policy Project of the Federation of America.
 

Matthias Emanuel Liechti,MD
 
mliechti@bli.unizh.ch
 
University Hospital of Psychiatry Zurich, Research Unit, PO Box 68, CH-8029 Zurich, Switzerland

Dr. Liechti is a medical doctor working in internal medicine and psychiatry. As a postdoctoral fellow and researcher he specialized in neuropsychopharmacology and elucidated the neuropharmacological mechanisms of MDMA's effects in humans.
 

Jessica E. Malberg, Ph.D.
 
Postdoctoral Associate, Dept. of Psychiatry, Yale University
 
jessica.malberg@yale.edu
 
34 Park St. , Dept. of Psychiatry, Room S-310,
Connecticut Mental Health Center, New Haven, CT  06508
 
Dr. Jessica Malberg received her Ph.D. from the University of Chicago in 1998, where she worked in the laboratory of Dr. Lewis Seiden and published the first papers investigating the interaction of environmental temperature, core body temperature and MDMA-induced neurotoxicity in the rat. She is currently a Post-Doctoral Associate at Yale University in the Department of Psychiatry, working in the laboratory of Molecular Psychiatry.
 

Ralph Metzner, Ph.D.

Professor of Psychology, California Institute of Integral Studies

rmetzner@svn.net

Dr. Ralph Metzner is a consciousness researcher and psychotherapist who worked with MDMA in psychotherapy prior to its prohibition. He is the pseudonymous editor of Through the Gateway of the Heart (1984), a compilation of experiential accounts of MDMA assisted therapy and meditation. He is also the co-author of The Psychedelic Experience (1964) with Timothy Leary, and the editor of Ayahuasca- Human Consciousness and the Spirits of Nature (1999).
 

John Mendelson MD
 
Associate Clinical Professor of Psychiatry and Medicine,
 Drug Dependence Research Center, University of California at San Francisco

Langley Porter Institute, Box CPR 0984
San Francisco, CA 94143
 
jemmd@itsa.ucsf.edu

Dr. Mendelson is an Internist interested in the human pharmacology of abused drugs.  He is among the first to study the effects of controlled doses of MDMA on cardiovascular function and to investigate the pharmacokinetics of MDMA in people.
 

Michael Montagne, R.Ph., Ph.D.
 
Rombult Distinguished Professor of Pharmacy, Massachusetts College of Pharmacy & Health Science
 
Massachusetts College of Pharmacy & Health Sciences,179 Longwood Ave., Boston MA 02115

mmontagne@mcp.edu

Dr. Michael Montagne has researched and taught on the social-cultural aspects of psychedelic drugs and their use for 25 years. His research also has focused on the role of meaning, symbolism, and metaphors in depression and the use of anti-depressant medications.
 

Claudio Naranjo, MD

hermesalud@euskalnet.net

President and program coordinator of SAT Institute (an integrative pycho-spiritual school
for psychotherapists and educators)
Fellow of the Institute for Cultural Research, London
Adviser to Lama Gangchen's World Peace Foundation
 
Dr. Claudio Naranjo was originally trained in psychiatry and psychoanalytic therapy, and became one of the three successors to Fritz Perls at Esalen Institute. He later became known as an author, an educator and an integrator between the world of psychotherapy and that of the spiritual traditions. He was the first to observe the characteristic effects of MDA and to point out the usefulness of MDA in psychotherapy. He was the first to point out the characteristic effects of the ' feeling enhancers' (now called empathogens) and to conduct clinical research with them.

 
Dave Nichols, PhD
 
Professor of Medicinal Chemistry and Molecular Pharmacology,
 
School of Pharmacy & Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907.
 
Dr. David Nichols has been at Purdue University since 1974 where he has published more than 200 scientific research articles on various aspects of the medicinal chemistry and neuropharmacology of drugs that act in the brain. He is internationally recognized for his research on understanding how changes in brain neurochemistry affect behavior, through the use of specific molecular probes. His laboratory carried out the first studies to establish the pharmacological mechanism of action of MDMA, and he has published numerous articles elucidating details both of the mechanism of action and of the biochemistry related to the neurotoxic effects of MDMA seen in rodents.  Dr. Nichols' work has clearly shown that MDMA is neither an hallucinogen or a psychostimulant, and it was he who coined the term "entactogens" as a name for the novel pharmacological class of which MDMA is the prototype.
 

June Riedlinger, Pharm.D.
 
Assistant Professor of Clinical Pharmacy and Director, Center for Integrative Therapies in Pharmaceutical Care, Massachusetts College of Pharmacy and Health Sciences
 
Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115-5896.

Dr. June Riedlinger is a registered pharmacist. She took the witness stand to testify as to the therapeutic effects of MDMA in 1985 and subsequently authored and co-authored articles on MDMA that have been published in the Journal of Psychoactive Drugs and has presented at the Drug Policy Foundation International conferences. Dr. Riedlinger is presently working in the Complementary and Alternative Medicine field through which she has been able to offer educational programs that include topics relating to psychedelic drugs and MDMA.
 

Joseph G. Rella, MD
Assistant Professor of Emergency Medicine, Department of Surgery
University of Medicine and Dentistry of New Jersey at Newark

UMDNJ Newark,150 Bergen Street, C-384, University Heights, Newark NJ 07103

After training in emergency medicine and completing a fellowship in medical toxicology in New York City, Dr. Joseph Rella collected data regarding MDMA toxicity in patients who were reported to the New York City poison center for 7 years. He is well-acquainted with the acute toxicity of MDMA and is continuing resesarch into its physiologic effects.
 

Douglas Rushkoff, PhD.

Professor of Virtual Culture at New York University's Interactive Telecommunication Program.

http://www.rushkoff.com
 
New York University Interactive Telecommunications Program, 721 Broadway, 4th Floor
New York, NY 10003

Prof. Douglas Rushkoff is the author of seven best-selling books on culture and technology, including Coercion, Media Virus, Cyberia, Playing the Future, and the novels Ecstasy Club and Exit Strategy, that have been translated into 13 languages. He writes a column for the New York Times Syndicate, delivers commentaries on National Public Radio, and makes documentaries for PBS Frontline. He has been studying psychedelic subcultures since he became friends with Timothy Leary in 1988.
 

José Carlos Bouso Saiz

Psychologist, PhD candidate, Facultad de Psicologia, Universidad Autonoma de Madrid

Departamento de Psicologia Biologica y de la Salud
Facultad de Psicologia, Universidad Autonoma de Madrid
28049 Cantoblanco, Madrid, Spain

Mr. José Carlos Bouso Saiz graduated with a degree in Psychology from the Universidad Autonoma de Madrid in 1994.  From 1994 to 1998, he collaborated in research related to psychotherapy, psychopharmacology and computerized cerebral cartography at the Department of Biologic Psychology and Health at the Faculty of Psychology. Mr. Bouso is currently developing the first officialy authorized MDMA/PTSD controlled psychotherapy study at the Psychiatric Hospital of Madrid, and will focus on this work for his PhD dissertation.
 

Rabbi Zalman Schacter-Shalomi

Professor of Religious Studies at Naropa University
Professor Emeritus of Religion at Temple University.

1720 Lehigh St.
Boulder, CO 80305
 

Rabbi Zalman Schachter-Shalomi is an ordained Lubavitch-trained rabbi whose belief in the universality of spiritual truth led him to study with Sufi Masters, Buddhist teachers, Native American elders, Catholic monks, and humanistic and transpersonal psychologists. As such he also experienced psychedelics and wrote about his experience in The Ecstatic Adventure. He is
founder of the trans-denominational Spiritual Eldering Institute headquartered in Boulder Colorado, which sponsors workshops providing the psychological and spiritual tools for people of all ages to grow into elderhood. On the faculty at Naropa University, he is the author of Spiritual Intimacy, and co-author of  Paradigm Shift with Ronald Millerand From Age-ing to Sage-ing.